Literature DB >> 9588921

Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.

L J Boersma1, M van den Brink, A M Bruce, T Shouman, L Gras, A te Velde, J V Lebesque.   

Abstract

PURPOSE: To investigate whether Dose-Volume Histogram (DVH) parameters can be used to identify risk groups for developing late gastrointestinal (GI) and genitourinary (GU) complications after conformal radiotherapy for prostate cancer. METHODS AND MATERIALS: DVH parameters were analyzed for 130 patients with localized prostate cancer, treated with conformal radiotherapy in a dose-escalating protocol (70-78 Gy, 2 Gy per fraction). The incidence of late (>6 months) GI and GU complications was classified using the RTOG/EORTC and the SOMA/LENT scoring system. In addition, GI complications were divided in nonsevere and severe (requiring one or more laser treatments or blood transfusions) rectal bleeding. The median follow-up time was 24 months. We investigated whether rectal and bladder wall volumes, irradiated to various dose levels, correlated with the observed actuarial incidences of GI and GU complications, using volume as a continuous variable. Subsequently, for each dose level in the DVH, the rectal wall volumes were dichotomized using different volumes as cutoff levels. The impact of the total radiation dose, and the maximum radiation dose in the rectal and bladder wall was analyzed as well.
RESULTS: The actuarial incidence at 2 years for GI complications > or =Grade II was 14% (RTOG/EORTC) or 20% (SOMA/LENT); for GU complications > or =Grade III 8% (RTOG/EORTC) or 21% (SOMA/LENT). Neither for GI complications > or =Grade II (RTOG/EORTC or SOMA/LENT), nor for GU complications > or =Grade III (RTOG/EORTC or SOMA/LENT), was a significant correlation found between any of the DVH parameters and the actuarial incidence of complications. For severe rectal bleeding (actuarial incidence at 2 years 3%), four consecutive volume cutoff levels were found, which significantly discriminated between high and low risk. A trend was observed that a total radiation dose > or = 74 Gy (or a maximum radiation dose in the rectal wall >75 Gy) resulted in a higher incidence of severe rectal bleeding (p = 0.07).
CONCLUSIONS: These data show that dose escalation up to 78 Gy, using a conformal technique, is feasible. However, these data have also demonstrated that the incidence of severe late rectal bleeding is increased above certain dose-volume thresholds.

Entities:  

Mesh:

Year:  1998        PMID: 9588921     DOI: 10.1016/s0360-3016(98)00037-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  49 in total

Review 1.  Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Authors:  Alan Pollack; Alex Hanlon; Eric M Horwitz; Steven Feigenberg; Robert G Uzzo; Robert A Price
Journal:  World J Urol       Date:  2003-09-05       Impact factor: 4.226

2.  A simulation technique for computation of the dosimetric effects of setup, organ motion and delineation uncertainties in radiotherapy.

Authors:  Bongile Mzenda; Mir Hosseini-Ashrafi; Antony Palmer; Honghai Liu; David J Brown
Journal:  Med Biol Eng Comput       Date:  2010-04-23       Impact factor: 2.602

3.  Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.

Authors:  David L Schwartz; Katherine Hutcheson; Denise Barringer; Susan L Tucker; Merrill Kies; F Christopher Holsinger; K Kian Ang; William H Morrison; David I Rosenthal; Adam S Garden; Lei Dong; Jan S Lewin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

4.  Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes.

Authors:  Yusung Kim; Wolfgang A Tomé
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-01       Impact factor: 7.038

5.  Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.

Authors:  Pilar M Samper; M Concepción López Carrizosa; Ana Pérez Casas; Carmen Vallejo; M Carmen Rubio Rodríguez; Consuelo Pérez Vara; Miguel Melchor Iñiguez
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

6.  Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models.

Authors:  Matthias Söhn; Di Yan; Jian Liang; Elisa Meldolesi; Carlos Vargas; Markus Alber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-26       Impact factor: 7.038

7.  Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

Authors:  Alexei Trofimov; Paul L Nguyen; John J Coen; Karen P Doppke; Robert J Schneider; Judith A Adams; Thomas R Bortfeld; Anthony L Zietman; Thomas F Delaney; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-21       Impact factor: 7.038

Review 8.  Current status of intensity-modulated radiation therapy (IMRT).

Authors:  Kazuo Hatano; Hitoshi Araki; Mitsuhiro Sakai; Takashi Kodama; Naoki Tohyama; Tohru Kawachi; Masaharu Imazeki; Takayuki Shimizu; Tsutomu Iwase; Minoru Shinozuka; Hideyo Ishigaki
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

9.  Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study).

Authors:  Krista Dawdy; Katija Bonin; Steve Russell; Agnes Ryzynski; Tamara Harth; Christopher Townsend; Stanley Liu; William Chu; Patrick Cheung; Hans Chung; Gerard Morton; Danny Vesprini; Andrew Loblaw; Xingshan Cao; Ewa Szumacher
Journal:  J Cancer Educ       Date:  2018-06       Impact factor: 2.037

10.  Comparison of rectal volume definition techniques and their influence on rectal toxicity in patients with prostate cancer treated with 3D conformal radiotherapy: a dose-volume analysis.

Authors:  Cem Onal; Erkan Topkan; Esma Efe; Melek Yavuz; Serhat Sonmez; Aydin Yavuz
Journal:  Radiat Oncol       Date:  2009-05-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.